Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

2.

Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorder.

Sikirica V, Fridman M, Bruno A, Hodgkins P, Erder MH.

Drugs R D. 2013 Dec;13(4):271-80. doi: 10.1007/s40268-013-0034-4.

3.

Disposition and metabolism of setipiprant, a selective oral CRTH2 antagonist, in humans.

Hoch M, Wank J, Kluge I, Wagner-Redeker W, Dingemanse J.

Drugs R D. 2013 Dec;13(4):253-69. doi: 10.1007/s40268-013-0031-7.

4.

An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.

Hobbs D, Karagianis J, Treuer T, Raskin J.

Drugs R D. 2013 Dec;13(4):281-8. doi: 10.1007/s40268-013-0030-8.

5.

The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.

Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C.

Drugs R D. 2013 Dec;13(4):243-52. doi: 10.1007/s40268-013-0029-1.

6.
8.

Inhaler competence and patient satisfaction with Easyhaler®: results of two real-life multicentre studies in asthma and COPD.

Gálffy G, Mezei G, Németh G, Tamási L, Müller V, Selroos O, Orosz M.

Drugs R D. 2013 Sep;13(3):215-22. doi: 10.1007/s40268-013-0027-3.

9.

Use of nicotinamide to treat hyperphosphatemia in dialysis patients.

Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy ZA.

Drugs R D. 2013 Sep;13(3):165-73. doi: 10.1007/s40268-013-0024-6. Review.

10.
11.

Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case series.

Maina MW, Pastakia SD, Manji I, Kirui N, Kirwa C, Karwa R.

Drugs R D. 2013 Sep;13(3):191-7. doi: 10.1007/s40268-013-0023-7.

12.
13.

Serum concentration of lignocaine after pertubation: an observational study.

Wickström K, Spira J, Edelstam G.

Drugs R D. 2013 Sep;13(3):235-9. doi: 10.1007/s40268-013-0022-8.

14.

Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function.

Rabadi MH, Kreymborg K, Vincent AS.

Drugs R D. 2013 Sep;13(3):175-81. doi: 10.1007/s40268-013-0020-x.

15.

Risk of falling and hypnotic drugs: retrospective study of inpatients.

Obayashi K, Araki T, Nakamura K, Kurabayashi M, Nojima Y, Hara K, Nakamura T, Yamamoto K.

Drugs R D. 2013 Jun;13(2):159-64. doi: 10.1007/s40268-013-0019-3.

16.

Evaluation of crushed ticagrelor tablet doses: recovery following crushing and naso-gastric tube passage ex vivo.

Crean B, Finnie C, Crosby A.

Drugs R D. 2013 Jun;13(2):153-7. doi: 10.1007/s40268-013-0018-4.

17.

Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects.

Dingemanse J, Hoever P.

Drugs R D. 2013 Jun;13(2):145-51. doi: 10.1007/s40268-013-0017-5.

18.

Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects.

Falcão A, Lima R, Sousa R, Nunes T, Soares-da-Silva P.

Drugs R D. 2013 Jun;13(2):137-43. doi: 10.1007/s40268-013-0016-6.

19.

Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: a single-dose, randomized, two-period crossover study in healthy volunteers.

Videla S, Cebrecos J, Lahjou M, Wagner F, Guibord P, Xu Z, Cabot A, Encabo M, Encina G, Sicard E, Sans A.

Drugs R D. 2013 Jun;13(2):129-35. doi: 10.1007/s40268-013-0015-7.

20.

Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.

Roesch B, Corcoran ME, Fetterolf J, Haffey M, Martin P, Preston P, Purkayastha J, Wang P, Ermer J.

Drugs R D. 2013 Jun;13(2):119-28. doi: 10.1007/s40268-013-0014-8.

Supplemental Content

Loading ...
Support Center